February 17th 2021
The first patient with operable, locally or regionally advanced melanoma has been dosed with the intratumoral DNA plasmid-based interleukin-12 therapy tavokinogene telseplasmid in combination with nivolumab as a neoadjuvant treatment before surgery in the investigator-initiated, phase 2 OMS-104 trial.
February 5th 2021
February 5, 2021 - The potent CDK9 inhibitor zotiraciclib, when used in combination was temozolomide, was found to induce clinically meaningful efficacy with a tolerable safety profile in patients with recurrent, high-grade gliomas.
February 4th 2021
In a year marked by collaboration and innovation, therapeutic developments in oncology care once again dominated the novel drug approvals in 2020.
February 2nd 2021
Biond Biologics Ltd. will join Sanofi in an exclusive worldwide license agreement for the development and commercialization of the novel immunotherapy BND-22.
January 29th 2021
January 29, 2021 - Dana-Farber Cancer Institute has announced the launch of its first-ever venture fund, Binney Street Capital, LLC.